U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Pancreatic Ductal Adenocarcinoma

MedGen UID:
1712889
•Concept ID:
C5237191
•
Neoplastic Process

Definition

Pancreatic ductal adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Pancreatic Ductal Adenocarcinoma

Professional guidelines

PubMed

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T
Cancer 2017 Dec 1;123(23):4680-4686. Epub 2017 Aug 17 doi: 10.1002/cncr.30927. PMID: 28817187

Recent clinical studies

Etiology

Targeting BRCA and PALB2 in Pancreatic Cancer.
Anbil S, Reiss KA
Curr Treat Options Oncol 2024 Mar;25(3):346-363. Epub 2024 Jan 4 doi: 10.1007/s11864-023-01174-0. PMID: 38311708
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hannigan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D'Andrea AD, Aguirre AJ, Shapiro GI, Cleary JM
Clin Cancer Res 2023 Dec 15;29(24):5047-5056. doi: 10.1158/1078-0432.CCR-23-2005. PMID: 37819936Free PMC Article
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.
Dev R, Fortuno ES 3rd, Amaram-Davila JS, Haider A, Bruera E
Ann Palliat Med 2023 May;12(3):600-606. Epub 2023 Mar 14 doi: 10.21037/apm-22-1167. PMID: 37038067
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma.
Chung C, Galvin R, Achenbach E, Dziadkowiec O, Sen S
Oncology (Williston Park) 2021 Dec 23;35(12):794-803. doi: 10.46883/2021.25920931. PMID: 35089001
Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H, Acharjee A, Eppenberger-Castori S, Gloor B, Gruber T, Schenk M, Karamitopoulou E
Front Immunol 2021;12:643529. Epub 2021 Feb 19 doi: 10.3389/fimmu.2021.643529. PMID: 33679807Free PMC Article

Diagnosis

Pancreatic Cancer Research beyond DNA Mutations.
Sato H, Sasaki K, Hara T, Tsuji Y, Arao Y, Otsuka C, Hamano Y, Ogita M, Kobayashi S, di Luccio E, Hirotsu T, Doki Y, Eguchi H, Satoh T, Uchida S, Ishii H
Biomolecules 2022 Oct 17;12(10) doi: 10.3390/biom12101503. PMID: 36291712Free PMC Article
Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R, Annis J, Nikolova O, Whatcott C, Gurley K, Mendez E, Moran-Jones K, Dorrell C, Sears RC, Kuo C, Han H, Biankin A, Grandori C, Von Hoff DD, Kemp CJ
Cancer Res 2022 Sep 16;82(18):3375-3393. doi: 10.1158/0008-5472.CAN-21-4222. PMID: 35819261Free PMC Article
Altered glycosylation in pancreatic cancer and beyond.
Lumibao JC, Tremblay JR, Hsu J, Engle DD
J Exp Med 2022 Jun 6;219(6) Epub 2022 May 6 doi: 10.1084/jem.20211505. PMID: 35522218Free PMC Article
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL
Mol Ther 2019 Nov 6;27(11):1919-1929. Epub 2019 Jul 30 doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241Free PMC Article
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V, Ribatti D, Silvestris N
Oncotarget 2016 Sep 6;7(36):58649-58658. doi: 10.18632/oncotarget.10765. PMID: 27462915Free PMC Article

Therapy

Pancreatic Cancer Research beyond DNA Mutations.
Sato H, Sasaki K, Hara T, Tsuji Y, Arao Y, Otsuka C, Hamano Y, Ogita M, Kobayashi S, di Luccio E, Hirotsu T, Doki Y, Eguchi H, Satoh T, Uchida S, Ishii H
Biomolecules 2022 Oct 17;12(10) doi: 10.3390/biom12101503. PMID: 36291712Free PMC Article
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ
Ann Oncol 2021 Jun;32(6):746-756. Epub 2021 Mar 16 doi: 10.1016/j.annonc.2021.03.005. PMID: 33741442
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL
Mol Ther 2019 Nov 6;27(11):1919-1929. Epub 2019 Jul 30 doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241Free PMC Article
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH
Gastroenterology 2018 Jul;155(1):29-32. Epub 2018 Mar 20 doi: 10.1053/j.gastro.2018.03.029. PMID: 29567081Free PMC Article
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA
Science 2009 Jun 12;324(5933):1457-61. Epub 2009 May 21 doi: 10.1126/science.1171362. PMID: 19460966Free PMC Article

Prognosis

The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment.
Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K
Cancer Sci 2023 Jan;114(1):16-24. Epub 2022 Oct 19 doi: 10.1111/cas.15609. PMID: 36197901Free PMC Article
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment.
Hwang WL, Jagadeesh KA, Guo JA, Hoffman HI, Yadollahpour P, Reeves JW, Mohan R, Drokhlyansky E, Van Wittenberghe N, Ashenberg O, Farhi SL, Schapiro D, Divakar P, Miller E, Zollinger DR, Eng G, Schenkel JM, Su J, Shiau C, Yu P, Freed-Pastor WA, Abbondanza D, Mehta A, Gould J, Lambden C, Porter CBM, Tsankov A, Dionne D, Waldman J, Cuoco MS, Nguyen L, Delorey T, Phillips D, Barth JL, Kem M, Rodrigues C, Ciprani D, Roldan J, Zelga P, Jorgji V, Chen JH, Ely Z, Zhao D, Fuhrman K, Fropf R, Beechem JM, Loeffler JS, Ryan DP, Weekes CD, Ferrone CR, Qadan M, Aryee MJ, Jain RK, Neuberg DS, Wo JY, Hong TS, Xavier R, Aguirre AJ, Rozenblatt-Rosen O, Mino-Kenudson M, Castillo CF, Liss AS, Ting DT, Jacks T, Regev A
Nat Genet 2022 Aug;54(8):1178-1191. Epub 2022 Jul 28 doi: 10.1038/s41588-022-01134-8. PMID: 35902743Free PMC Article
Altered glycosylation in pancreatic cancer and beyond.
Lumibao JC, Tremblay JR, Hsu J, Engle DD
J Exp Med 2022 Jun 6;219(6) Epub 2022 May 6 doi: 10.1084/jem.20211505. PMID: 35522218Free PMC Article
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM
Cancer Discov 2021 Aug;11(8):2014-2031. Epub 2021 Mar 16 doi: 10.1158/2159-8290.CD-20-0841. PMID: 33727309Free PMC Article
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Li J, Yuan S, Norgard RJ, Yan F, Sun YH, Kim IK, Merrell AJ, Sela Y, Jiang Y, Bhanu NV, Garcia BA, Vonderheide RH, Blanco A, Stanger BZ
Cancer Discov 2021 Mar;11(3):736-753. Epub 2020 Nov 6 doi: 10.1158/2159-8290.CD-20-0519. PMID: 33158848Free PMC Article

Clinical prediction guides

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA
J Immunother Cancer 2024 Feb 2;12(2) doi: 10.1136/jitc-2023-006822. PMID: 38309721Free PMC Article
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hannigan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D'Andrea AD, Aguirre AJ, Shapiro GI, Cleary JM
Clin Cancer Res 2023 Dec 15;29(24):5047-5056. doi: 10.1158/1078-0432.CCR-23-2005. PMID: 37819936Free PMC Article
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, Peer E, Denroche RE, Zhang A, Notta F, Wilson JM, O'Kane GM, Haimov Talmoud E, Amison N, Schvimer M, Salpeter SJ, Bar V, Zundelevich A, Tirosh I, Tal R, Dinstag G, Kinar Y, Eliezer Y, Ben-David U, Gavert NS, Straussman R, Gallinger SJ, Berger R, Golan T
Cancer Discov 2023 Aug 4;13(8):1826-1843. doi: 10.1158/2159-8290.CD-22-0412. PMID: 37449843Free PMC Article
Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y, Liu Q, Cui M, Wang M, Hua S, Gao J, Liao Q
Front Immunol 2021;12:774435. Epub 2022 Jan 3 doi: 10.3389/fimmu.2021.774435. PMID: 35046938Free PMC Article
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM
Cancer Discov 2021 Aug;11(8):2014-2031. Epub 2021 Mar 16 doi: 10.1158/2159-8290.CD-20-0841. PMID: 33727309Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...